Word: anticholesterol
(lookup in dictionary)
(lookup stats)
Dates: during 1980-1989
Sort By: most recent first
(reverse)
...right? Up to a point, yes. Many of his criticisms of the anticholesterol campaign have been voiced by respected researchers in the New England Journal of Medicine and the Journal of the American Medical Association. Certainly, many people have an overly simplistic view of the relationship between diet and heart disease. Observes Dr. Allan Brett, an assistant professor at the Harvard Medical School: "Some patients have been led to believe that lowering cholesterol is like magic: eat a bowl of oat bran, and you're cured. For most, that's not true...
...used only after diet modification fails, many doctors are too quick to reach for the prescription pad. Reason: patients find it easier to take pills than to give up steak and eggs. Yet taking drugs for a lifetime can have unintended and perhaps dangerous side effects. The well-established anticholesterol drugs, including cholestyramine and nicotinic acid, seem to be relatively safe, but they can produce such discomforts as nausea and intestinal pain. Newer drugs, like the heavily promoted lovastatin, may be better tolerated, but their long-term safety and effectiveness have not been established. Moreover, reducing cholesterol...
...BIGGEST BEEF Considered a villain by anticholesterol forces, beef has taken a drubbing in sales in recent years. Now, thanks in part to a diligent advertising campaign ("beef: real food for real people") and undoubtedly to the natural longing for this most American of meats, sales are increasing in many parts of the country, in some areas as much as 20%. But many butchers bow to the times and trim all visible gristle...
...world's No. 1 prescription drugmaker. Though many Americans probably could not name a single Merck product, especially since its Sucrets sore-throat lozenge and Calgon bubble- bath brands were sold in 1977, physicians and pharmacists are very familiar with the company's 100 drugs, from antibiotics to anticholesterol pills. Merck's sales surged by 23% in 1987, to a record $5.1 billion, as profits ballooned by 34%, to $906.4 million...
...potential, Mevacor faces stiff competition. Lopid, a similar drug introduced in 1982 by Parke-Davis, had about 40% of the $190 million anticholesterol business when Mevacor appeared on druggists' shelves in September. Mevacor quickly grabbed a 33% share, trimming Lopid's to 20%. Then, in November, Parke-Davis came out with a study quantifying how Lopid dramatically cuts the risk of coronary heart disease. Lacking his own data, Vagelos refused to make similar assertions. By January the two drugs were running about even in sales. Analysts suggest, however, that once Merck has its own study in hand, the company...